pneumonia
caus
mycoplasma
pneumonia
mp
usual
benign
selflimit
diseas
treat
effect
macrolid
howev
pediatr
case
may
develop
sever
lifethreaten
infect
resist
convent
macrolid
treatment
refractori
mp
pneumonia
character
prolong
fever
accompani
deterior
radiolog
find
respond
appropri
macrolid
therapi
glucocorticoid
may
effect
well
toler
case
mp
pneumonia
host
cellmedi
immun
play
key
role
develop
pulmonari
lesion
studi
immunocompromis
host
suggest
cell
play
role
pathogenesi
mycoplasma
infect
support
appar
correl
develop
delay
hypersensit
skin
reaction
mp
infect
sever
diseas
case
mp
pneumonia
activ
host
immun
respons
promot
releas
cytokin
thelper
th
immun
respons
may
contribut
sever
pulmonari
injuri
furthermor
mp
pneumonia
may
relat
mononuclear
cell
infiltr
airway
mainli
compos
cell
contribut
substanti
amplif
immun
respons
subsequ
injuri
lung
parenchyma
lactat
dehydrogenas
ldh
oxidoreductas
catalyz
interconvers
pyruv
lactat
concomit
interconvers
nadh
nad
occasion
term
hydroxybutyr
dehydrogenas
also
catalyz
oxid
hydroxybutyr
cytoplasm
enzym
present
major
organ
includ
brain
kidney
liver
myocardium
lung
cell
lysi
occur
cell
membran
damag
ldh
releas
extracellular
space
therefor
ldh
level
use
surrog
marker
tissu
breakdown
previou
studi
shown
serum
ldh
level
increas
patient
refractori
mp
pneumonia
includ
children
requir
steroid
therapi
propos
ldh
use
initi
indic
refractori
mp
pneumonia
although
studi
necessari
confirm
use
serum
ldh
level
indic
sever
need
steroid
therapi
mp
pneumonia
cell
play
potent
proinflammatori
role
immun
system
produc
signatur
cytokin
interleukin
lesser
extent
inflamm
mediat
includ
interleukin
tumor
necrosi
addit
effector
function
defens
extracellular
pathogen
cell
promot
mani
inflammatori
condit
includ
sever
lung
diseas
chronic
obstruct
pulmonari
diseas
mice
inocul
live
mp
bronchoalveolar
lavag
fluid
increas
concentr
neutrophil
count
similarli
signal
activ
observ
patient
mp
pneumonia
show
significantli
higher
level
serum
streptococc
pneumonia
sinc
found
play
role
transit
innat
immun
adapt
immun
observ
lead
hypothesi
compon
mp
extract
induc
turn
caus
excess
inflammatori
cell
reaction
observ
mp
pneumonia
patient
interleukin
proinflammatori
cytokin
promot
cytokin
respons
recent
studi
reveal
elev
level
serum
children
mp
pneumonia
level
rose
acut
phase
infect
ferritin
induc
activ
macrophag
produc
earli
stage
infect
phagocyt
cell
stimul
synthet
releas
cytokin
turn
stimul
synthesi
ferritin
increas
serum
level
ferritin
exert
immunosuppress
effect
inhibit
lymphocyt
prolifer
excess
ferritin
also
reflect
increas
level
import
apoptot
factor
cytotox
marker
aspart
aminotransferas
ldh
creatin
kinas
indic
increas
apoptosi
mechan
underli
effect
steroid
mp
pneumonia
remain
unknown
rapid
improv
clinic
symptom
pulmonari
lesion
follow
steroid
administr
suggest
increas
relat
activ
cytokin
result
immunolog
dysregul
may
play
crucial
role
recent
evid
indic
pathogenesi
similar
mp
respons
develop
acut
respiratori
distress
syndrom
multiorgan
failur
sever
viral
infect
sever
acut
respiratori
syndrom
viral
diseas
share
common
laboratori
find
high
serum
level
ferritin
ldh
similar
observ
patient
refractori
mp
pneumonia
accumul
evid
shown
highdos
corticosteroid
effect
patient
mp
infect
combin
therapi
macrolid
system
steroid
effect
reduc
mpinduc
pulmonari
inflamm
use
either
agent
alon
data
lend
support
clinic
observ
murin
model
show
addit
system
steroid
antimicrobi
may
aid
treatment
sever
mp
infect
specif
compar
effect
treatment
macrolid
system
steroid
combin
patient
mp
respiratori
tract
infect
fulli
investig
effect
system
steroid
infectioninduc
airway
inflamm
airway
function
complet
understood
particularli
relat
infecti
asthma
remain
investig
whether
refractori
common
mp
pneumonia
differ
respons
macrolid
therefor
present
studi
aim
investig
cytokin
relat
respons
mechan
identifi
initi
biomark
may
distinguish
common
refractori
mp
pneumonia
hospit
admiss
addit
investig
critic
cutoff
valu
relev
biomark
includ
ldh
ferritin
identifi
may
use
differenti
diagnosi
refractori
common
mp
pneumonia
hospit
admiss
cohort
includ
children
mp
pneumonia
admit
depart
pediatr
hanyang
univers
guri
hospit
seoul
korea
octob
march
hospit
admiss
children
receiv
physic
examin
routin
laboratori
test
assess
clinic
symptom
fever
temperatur
paroxysm
dri
hack
cough
without
sputum
abdomin
pain
skin
erupt
chest
radiograph
analyz
written
inform
consent
obtain
parent
allow
patient
undergo
serum
blood
test
respiratori
viru
examin
mycoplasma
igm
test
serum
sampl
save
later
evalu
biomark
cytokin
patient
classifi
accord
pneumonia
type
patient
mp
pneumonia
treatment
initi
macrolid
antibiot
clarithromycin
h
patient
check
reduct
fever
cough
crackl
lung
well
improv
radiolog
find
improv
patient
consid
refractori
mp
pneumonia
start
system
steroid
addit
treatment
prevent
sequela
lung
refractori
mp
pneumonia
patient
adequ
dose
system
steroid
refractori
mp
pneumonia
establish
mani
studi
differ
type
steroid
use
differ
dose
use
methylprednisolon
antiinflammatori
dose
mgkgday
fig
children
discharg
hospit
improv
symptom
recoveri
hospit
discharg
children
classifi
five
group
fig
tabl
mp
pneumonia
without
document
viral
infect
receiv
macrolid
alon
group
mp
pneumonia
without
document
viral
infect
receiv
combin
therapi
macrolid
methylprednisolon
group
ii
mp
pneumonia
document
viral
infect
receiv
macrolid
antibiot
group
iii
viral
pneumonia
without
document
mp
infect
receiv
empir
antibiot
conserv
treatment
group
iv
control
recruit
among
children
admit
due
pneumonia
present
document
bacteri
viral
infect
includ
mp
receiv
antibiot
conserv
treatment
group
v
subdivid
five
group
group
includ
group
iii
iv
v
group
b
group
ii
accord
whether
respons
macrolid
treatment
studi
protocol
consent
form
approv
institut
review
board
hanyang
univers
approv
number
diagnosi
mp
pneumonia
base
clinic
symptom
fever
paroxysm
dri
hack
cough
dyspnea
crackl
well
result
radiolog
find
serolog
test
rather
use
classic
particl
agglutin
test
indirect
enzymelink
immunosorb
assay
kit
vircel
granada
spain
use
identifi
mp
caus
organ
pneumonia
antigen
compos
extract
inactiv
mp
bound
solid
phase
incub
dilut
patient
serum
sampl
block
igg
antibodi
specif
igm
protein
bound
antigen
wash
elimin
unreact
protein
sampl
incub
conjug
consist
antihuman
igm
monoclon
antibodi
peroxidas
conjug
react
elimin
peroxidas
substrat
ad
blue
color
develop
proport
concentr
specif
antibodi
present
test
serum
result
express
index
ratio
optic
densiti
test
sampl
cutoff
valu
could
use
quantit
measur
proport
amount
specif
igm
present
test
serum
consid
posit
ratio
previou
studi
shown
signific
differ
sensit
specif
enzymelink
immunosorb
assay
particl
agglutin
test
diagnosi
viral
pneumonia
base
respiratori
symptom
posit
radiograph
find
polymeras
chain
reaction
analysi
nasopharyng
secret
posit
respiratori
virus
admiss
sampl
nasopharyng
secret
obtain
nasopharynx
via
aspir
cathet
inject
ml
steril
physiolog
salin
solut
mucu
trap
specimen
independ
screen
presenc
common
respiratori
virus
includ
influenza
virus
parainfluenza
virus
human
coronavirus
human
rhinovirus
human
metapneumovirus
human
adenovirus
respiratori
syncyti
virus
revers
transcriptionpolymeras
chain
reaction
use
commerci
kit
seeplex
rv
ace
detect
seegen
seoul
korea
venou
blood
obtain
subject
averag
time
blood
sampl
obtain
onset
diseas
symptom
day
obtain
blood
sampl
centrifug
min
store
serum
ldh
ferritin
level
measur
use
commerci
enzymelink
immunosorb
assay
dbd
inc
san
diego
ca
usa
accord
manufactur
instruct
detect
limit
pgml
statist
analys
perform
use
spss
version
spss
inc
chicago
il
usa
data
express
median
iqr
inter
quantil
rang
statist
comparison
made
use
kruskal
walli
test
mannwhitney
u
test
signific
probabl
p
valu
consid
statist
signific
kruskal
walli
test
use
compar
concentr
serum
ldh
ferritin
among
studi
group
mannwhitney
u
test
use
compar
concentr
serum
ldh
ferritin
among
studi
group
refractori
mp
vs
pneumonia
critic
cutoff
valu
refractori
mp
pneumonia
initi
biomark
compar
receiv
oper
characterist
roc
curv
analysi
total
children
pneumonia
admit
depart
pediatr
hanyang
univers
guri
hospit
includ
median
age
children
year
rang
year
tabl
present
demograph
characterist
children
within
five
group
differ
found
among
group
regard
sex
age
children
polymeras
chain
reaction
reveal
presenc
sever
viral
infect
within
group
iii
iv
includ
case
rhinoviru
case
influenza
case
parainfluenza
case
respiratori
syncyti
viru
case
adenoviru
case
coronaviru
group
iii
case
rhinoviru
case
influenza
case
parainfluenza
case
adenoviru
case
respiratori
syncyti
viru
group
iv
patient
present
doubl
viral
infect
serum
ldh
concentr
group
ii
median
iul
significantli
higher
group
iii
iv
v
median
iul
respect
p
fig
furthermor
comparison
serum
ldh
concentr
show
concentr
group
ii
significantli
higher
five
studi
group
subdivid
group
group
iii
iv
v
group
b
group
ii
fig
serum
concentr
group
ii
median
pgml
higher
group
iii
iv
v
pgml
respect
p
howev
signific
differ
level
group
ii
group
fig
signific
differ
found
level
group
b
fig
serum
concentr
measur
group
ii
median
pgml
significantli
higher
group
iii
iv
v
median
pgml
respect
p
fig
concentr
significantli
higher
group
b
group
fig
serum
ferritin
concentr
measur
group
ii
median
pgml
significantli
higher
group
iii
iv
v
median
pgml
respect
p
fig
concentr
serum
ferritin
concentr
group
b
significantli
higher
group
fig
signific
differ
found
among
group
regard
concentr
serum
fig
e
fig
e
cutoff
valu
biomark
cytokin
elev
patient
refractori
mp
pneumonia
group
ii
ie
ldh
ferritin
calcul
use
roc
curv
analysi
analysi
reveal
serum
ldh
concentr
iul
higher
sensit
specif
respect
serum
level
pgml
higher
sensit
specif
diagnosi
mp
pneumonia
respect
serum
ferritin
concentr
pgml
higher
sensit
specif
tabl
studi
investig
biomark
cytokin
distinguish
common
refractori
mp
pneumonia
hospit
admiss
found
level
serum
ldh
ferritin
increas
refractori
mp
group
indic
relev
biomark
diagnos
refractori
mp
pneumonia
studi
patient
mp
pneumonia
treatment
initi
macrolid
antibiot
clarithromycin
h
patient
check
reduct
fever
cough
crackl
lung
well
improv
radiolog
find
improv
patient
consid
refractori
mp
pneumonia
although
exact
definit
refractori
mp
pneumonia
present
guidelin
studi
defin
refractori
mp
pneumonia
improv
clinic
laboratori
find
day
macrolid
treatment
detect
treatment
failur
antibiot
mostli
base
object
clinic
criteria
also
less
welldefin
subject
decis
treat
physician
assess
respons
perform
earli
enough
allow
success
rescu
therapi
earli
allow
evid
clinic
respons
time
antibiot
respons
depend
site
infect
pathogen
patient
immunolog
statu
differ
symptom
sign
may
requir
differ
time
point
evalu
usual
h
need
proper
treatment
therefor
defin
h
standard
diagnos
refractori
mp
pneumonia
studi
consid
treatment
failur
absenc
symptomat
improv
h
macrolid
antibiot
treatment
ad
treatment
prevent
sequela
lung
system
steroid
mp
infect
occur
annual
worldwid
recent
mp
epidem
occur
infect
typic
begin
spread
autumn
remain
sever
month
mp
infect
start
adher
bacteria
host
cell
trigger
diseaserel
symptom
cytokin
affect
host
immun
respons
contribut
symptom
firstlin
antibiot
therapi
mp
pneumonia
macrolid
antibiot
howev
number
pediatr
patient
macroliderefractori
mp
pneumonia
increas
notic
korea
mp
pneumonia
preval
defin
refractori
mp
difficult
studi
diseas
publish
although
mani
studi
underway
consensu
treatment
protocol
refractori
mp
yet
reach
previou
studi
tamura
et
al
confirm
children
refractori
mp
pneumonia
cytopenia
well
increas
ldh
ferritin
also
demonstr
methylprednisolon
puls
therapi
improv
radiolog
abnorm
well
symptom
includ
fever
hirao
et
al
report
increas
level
acut
mp
pneumonia
associ
inflamm
describ
key
role
mani
furthermor
inamura
et
al
measur
increas
level
ldh
aspart
aminotransferas
alanin
aminotransferas
factor
refractori
mp
suggest
serum
level
would
use
marker
evalu
therapeut
efficaci
refractori
mp
pneumonia
could
use
criteria
decid
patient
candid
corticosteroid
therapi
although
studi
show
paramet
significantli
elev
refractori
mp
infect
dramat
decreas
corticosteroid
therapi
addit
studi
focus
variou
inflammatori
mediat
requir
elucid
mechan
action
knowledg
would
aid
determin
appropri
initi
therapi
present
studi
focus
level
ldh
ferritin
consid
primari
factor
refractori
mp
pneumonia
base
studi
present
also
subdivid
group
patient
mp
pneumonia
two
group
one
compris
patient
respond
well
macrolid
antibiot
anoth
compris
patient
receiv
corticosteroid
therapi
lack
respons
macrolid
compar
level
factor
subgroup
result
show
signific
differ
ldh
ferritin
level
pediatr
patient
refractori
nonrefractori
mp
pneumonia
also
determin
cutoff
valu
enzym
cytokin
use
diagnosi
refractori
mp
determin
cutoff
valu
appropri
sensit
specif
requir
order
appli
find
clinic
set
enzym
cytokin
level
cutoff
valu
use
indic
refractori
mp
pneumonia
allow
prompt
initi
adequ
treatment
previou
studi
investig
enzym
cytokin
elev
patient
refractori
mp
pneumonia
howev
diagnost
biomark
provid
inform
best
cours
treatment
therefor
investig
first
time
biomark
predict
respons
macrolid
therapi
although
investig
enzym
cytokin
also
elev
sever
infect
measur
togeth
use
diagnosi
refractori
mp
pneumonia
present
studi
limit
first
number
patient
rel
low
caus
group
size
small
second
account
possibl
coinfect
bacteria
virus
third
could
perform
sputum
cultur
confirm
macrolid
resist
mycoplasma
pneumonia
difficult
obtain
test
sputum
specimen
pediatr
patient
found
patient
refractori
mp
pneumonia
present
elev
level
serum
ldh
ferritin
hospit
admiss
suggest
taken
togeth
biomark
may
use
tool
distinguish
common
refractori
mp
pneumonia
well
mp
viral
pneumonia
hospit
admiss
find
allow
appropri
therapi
refractori
mp
pneumonia
combin
macrolid
treatment
administ
earlier
order
use
result
clinic
necessari
continu
studi
larger
number
subject
